Patents Examined by Sean McGarry
  • Patent number: 10570392
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 25, 2020
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • Patent number: 10570461
    Abstract: In one aspect, methods of detecting tumor cells are described herein. In some embodiments, a method of detecting tumor cells comprises providing a device, the device comprising a substrate surface and a plurality of first aptamer probes attached to the substrate surface. The method further comprises contacting a plurality of cells with the plurality of first aptamer probes attached to the substrate surface; adhering one or more of the plurality of cells to the substrate surface; and measuring a non-uniformity parameter, a Hausdorff distance, a change in the number of pseudopods, and/or a shape of at least one adhered cell. In some cases, the method further comprises using the non-uniformity parameter, Hausdorff distance, change in the number of pseudopods, and/or shape of the adhered cell to identify the adhered cell as a tumor cell or a non-tumor cell.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: February 25, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Samir M. Iqbal, Swati Goyal, Young-Tae Kim, Yuan Wan, Mohammed A. I. Mahmood, Umair J. M. Khan
  • Patent number: 10557139
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: February 11, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Patent number: 10557137
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: February 11, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
  • Patent number: 10557138
    Abstract: Compositions and methods for providing viral control in Varroa mites and bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in Varroa mites and bees by providing trigger polynucleotides targeting viral sequences is disclosed.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: February 11, 2020
    Assignee: BEEOLOGICS, INC.
    Inventors: Merav Gleit-Kielmanowicz, Yael Golani
  • Patent number: 10550389
    Abstract: The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: February 4, 2020
    Inventor: Roy C. Levitt
  • Patent number: 10550393
    Abstract: An object of the present invention is to provide a convenient and low-cost method for enhancing the stability of a DNA aptamer and/or its capacity to bind to a target molecule, and a DNA aptamer obtained by the method. The object is solved by substituting an internal hairpin structure (stem-loop structure) of the DNA aptamer with a structure called mini-hairpin structure and optionally increasing GC pairs in a stem portion of the DNA aptamer.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: February 4, 2020
    Assignee: Tagcyx Biotechnologies
    Inventors: Ichiro Hirao, Michiko Hirao, Kenichiro Matsunaga
  • Patent number: 10550390
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: February 4, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Patent number: 10537591
    Abstract: The invention solves the problem of providing new therapies that are effective in the treatment of muscular dystrophies through the use of compositions comprising a compound capable of reducing the expression of miRNA-106b in muscle satellite stem cells of a human or animal subject with respect to the expression observed in the absence of the compound in said cells.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: January 21, 2020
    Assignee: UNIVERSIDAD DE JAEN
    Inventors: Amelia Eva Aranega Jimenez, Diego Franco Jaime, Francisco Hernandez Torres, Estefania Lozano Velasco, Daniel Vallejo Pulido
  • Patent number: 10533172
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: January 14, 2020
    Assignee: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron
  • Patent number: 10533178
    Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: January 14, 2020
    Assignees: Ionis Pharmaceuticals, Inc., University of Utah Research Foundation
    Inventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
  • Patent number: 10519442
    Abstract: The present invention relates to compositions comprising TWIST signaling inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 31, 2019
    Assignee: City of Hope
    Inventors: Carlotta A. Glackin, John Rossi, Jeffrey I. Zink, Fuyuhiko Tamanoi, Cai M. Roberts, James Finlay
  • Patent number: 10513701
    Abstract: Therapeutic agent for use in the treatment of neurodegenerative diseases associated with abnormalities of MAPT gene encoded protein tau, wherein said therapeutic agent comprises one or more siRNAs targeting MAPT exon 10 sequence.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: December 24, 2019
    Assignee: UNIVERSITÀ DEGLI STUDI DI TRENTO
    Inventors: Giuseppina Covello, Michela Alessandra Denti, Kavitha Siva
  • Patent number: 10513703
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: December 24, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Stuart Milstein, Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Patent number: 10487106
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 26, 2019
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Patent number: 10472632
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: November 12, 2019
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • Patent number: 10472634
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to an LRP8 transcript. Certain such compounds are useful for hybridizing to an LRP8 transcript, including but not limited, to an LRP8 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRP8 transcript. In certain embodiments, such hybridization results in an increase in inclusion of exon 19 in the LRP8 mRNA transcript. In certain embodiments, such compounds are used to treat Alzheimer's Disease.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: November 12, 2019
    Assignees: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
    Inventors: Frank Rigo, Michelle L. Hastings
  • Patent number: 10473669
    Abstract: Methods of treating a subject with IBD with an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CRP levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CRP levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CRP levels may correlated with IBD remission or decreases in CDAI score. The present invention also relates to treatment of IBD using an anti-SMAD7 therapy (e.g., an antisense oligonucleotide) in combination with an additional agent. The invention also features related pharmaceutical compositions and kits.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 12, 2019
    Assignee: Nogra Pharma Limited
    Inventor: Giovanni Monteleone
  • Patent number: 10472649
    Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: November 12, 2019
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
  • Patent number: 10465251
    Abstract: A method of analyzing tissue in a subject having or suspected of having cancer includes obtaining an expression profile from a sample of tissue obtained from the subject, wherein the expression profile comprises the level of at least one esophageal adenocarcinoma associated lincRNA selected from the group consisting of linc-PRKD, lincRTL, lincMIA, lincNAV, and lincTMEM.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: November 5, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Kishore Guda, Amitabh Chak, AnnMarie Kieber-Emmons